General description
B-Myb, also known as B-Myb or Myb-like protein 2, and encoded by the gene MYBL2/BMYB, is a transcription factor protein involved in the regulation of cell survival, proliferation and differentiation. B-Myb is phosphorylated by cyclin A/cyclin-dependent kinase 2 during the S-phase of the cell cycle and possesses both activator and repressor activities. B-Myb is a component of the DREAM complex (also named LINC complex) that is composed of at least E2F4, E2F5, LIN9, LIN37, LIN52, LIN54, MYBL1, MYBL2, RBL1, RBL2, RBBP4, TFDP1 and TFDP2 proteins. The complex exists in quiescent cells where it represses cell cycle-dependent genes. It dissociates in S phase when LIN9, LIN37, LIN52 and LIN54 form a subcomplex that binds to MYBL22. B-Myb is localized to the nucleus. B-Myb is widely expressed and up regulated in cancer cells. B-Myb is an oncogenic transcription factor involved in G2/M progression and is a key target of anti-cancer therapy.
~80 kDa observed
Immunogen
Recombinant protein corresponding to human B-Myb.
Application
Detect B-Myb using this Anti-B-Myb Antibody, clone LX015.1 validated for use in western blotting.
Research Category
Epigenetics & Nuclear Function
Research Sub Category
Transcription Factors
Western Blotting Analysis: A representative lot from an independent laboratory detected U2OS cell lysates expressing B-Myb in U2OS (Chen, X., et al. (2013). Mol Cel Biol. 33(2):227-236.).
Western Blotting Analysis: A representative lot from an independent laboratory in NIH/3T3 cell lysates and in undifferentiated and differentiated F9 cell lysates (Knight, A. S., et al. (2009). Oncogene. 28(15):1737-1747.).
Western Blotting Analysis: A representative lot from an independent laboratory in cycling NIH/3T3 and F9 nuclear extracts (Muller, G. A., et al. (2012). Nucleic Acids Res. 40(4):1561-78.).
Western Blotting Analysis: A representative lot from an independent laboratory detected B-Myb wild-type cycling MEF cell lysates and not in B-Myb wild type G0 phase arrested MEF cell lysates. The same lot also detected B-Myb in G0 phase arrested and in cycling MEF cell lysates inappropriately expressing homozygous mutant B-Myb (Tavner, F., et al. (2007). Oncogene. 26(19): 2727-2735.).
Physical form
Format: Purified
Protein G Purified
Purified mouse monoclonal IgG1κ in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.
Preparation Note
Stable for 1 year at 2-8°C from date of receipt.
Analysis Note
Evaluated by Western Blotting in HEK293 cell lysate.
Western Blotting Analysis: 1 μg/mL of this antibody detected B-Myb in 10 μg of HEK293 cell lysate.
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
| biological source | mouse |
| Quality Segment | 100 |
| conjugate | unconjugated |
| antibody form | purified immunoglobulin |
| antibody product type | primary antibodies |
| clone | LX015.1, monoclonal |
| species reactivity | mouse, human |
| technique(s) | western blot: suitable |
| isotype | IgG1κ |
| NCBI accession no. | NP_002457 |
| UniProt accession no. | P10244 |
| shipped in | wet ice |
| target post-translational modification | unmodified |
| Gene Information | human ... MYBL2(4605) |
